PURPOSE: Hepatoblastoma (HB) has a poor prognosis in advanced stages. The aim of this study was to enhance effectiveness of chemotherapy with antineoplastic kinase inhibitors. METHODS: Viability was monitored in HB cells (HUH6, HepT1) in monolayer and spheroid cultures treated with kinase inhibitors VX-680, Wee1-InhibitorII, and SU11274 alone or in combination with cisplatin (CDDP) using MTT assays. Apoptosis was revealed by Caspase-3 assay. Western blot and immunohistochemical analyses were performed to determine histone H3 phosphorylation. RESULTS: Among the kinase inhibitors strongest anti-proliferative effect on HB cells was documented for VX-680. HUH6 cells responded more sensitively to the Aurora kinase inhibitor as HepT1 cells (IC(50) 8 and 16.6 μM, respectively). While VX-680 and CDDP showed no additive effects, the combination of VX-680 and histone deacetylase inhibitor SAHA had a synergistic effect on the proliferation of HUH6 cells. The inhibition with VX-680 led to reduced histone H3 phosphorylation, to an increase of apoptotic cells, and to morphological changes such as vacuolization and swelling of the cells and nuclei. CONCLUSION: The data provide evidence that VX-680 might improve treatment results in HB with increased Aurora kinase activity by inhibiting cell proliferation and induction of apoptosis.
PURPOSE: Hepatoblastoma (HB) has a poor prognosis in advanced stages. The aim of this study was to enhance effectiveness of chemotherapy with antineoplastic kinase inhibitors. METHODS: Viability was monitored in HB cells (HUH6, HepT1) in monolayer and spheroid cultures treated with kinase inhibitors VX-680, Wee1-InhibitorII, and SU11274 alone or in combination with cisplatin (CDDP) using MTT assays. Apoptosis was revealed by Caspase-3 assay. Western blot and immunohistochemical analyses were performed to determine histone H3 phosphorylation. RESULTS: Among the kinase inhibitors strongest anti-proliferative effect on HB cells was documented for VX-680. HUH6 cells responded more sensitively to the Aurora kinase inhibitor as HepT1 cells (IC(50) 8 and 16.6 μM, respectively). While VX-680 and CDDP showed no additive effects, the combination of VX-680 and histone deacetylase inhibitor SAHA had a synergistic effect on the proliferation of HUH6 cells. The inhibition with VX-680 led to reduced histone H3 phosphorylation, to an increase of apoptotic cells, and to morphological changes such as vacuolization and swelling of the cells and nuclei. CONCLUSION: The data provide evidence that VX-680 might improve treatment results in HB with increased Aurora kinase activity by inhibiting cell proliferation and induction of apoptosis.
Authors: Ayman El-Sheikh; Rong Fan; Diane Birks; Andrew Donson; Nicholas K Foreman; Rajeev Vibhakar Journal: Pediatr Blood Cancer Date: 2010-07-15 Impact factor: 3.167
Authors: L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo N Lara; David R Gandara Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Paraskevi Briassouli; Florence Chan; Kay Savage; Jorge S Reis-Filho; Spiros Linardopoulos Journal: Cancer Res Date: 2007-02-15 Impact factor: 12.701
Authors: Farid Gizatullin; Yao Yao; Victor Kung; Matthew W Harding; Massimo Loda; Geoffrey I Shapiro Journal: Cancer Res Date: 2006-08-01 Impact factor: 12.701
Authors: Lauren A Gillory; Jerry E Stewart; Michael L Megison; Hugh C Nabers; Elizabeth Mroczek-Musulman; Elizabeth A Beierle Journal: Transl Oncol Date: 2013-04-01 Impact factor: 4.243
Authors: V Ellerkamp; J Lieber; C Nagel; J Wenz; S W Warmann; J Fuchs; S Armeanu-Ebinger Journal: Pediatr Surg Int Date: 2012-12-25 Impact factor: 1.827
Authors: Christian Dittrich; Michael A Fridrik; Robert Koenigsberg; Chooi Lee; Rainer-Georg Goeldner; James Hilbert; Richard Greil Journal: Invest New Drugs Date: 2014-12-23 Impact factor: 3.850